Nucleic acid co-encapsulation method based on high-frequency oscillatory shear microfluidic technology, and use thereof

High-frequency oscillatory shearing microfluidic technology was used to achieve layered encapsulation and time-sequential release of nucleic acid drugs within lipid nanoparticles, solving the problem of precise control in nucleic acid co-delivery in existing technologies and improving the efficacy and safety of nucleic acid drugs.

WO2026233466A1PCT designated stage Publication Date: 2026-11-12HUZHOU LIYING BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/101910
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-14
Filing Date
2026-06-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing nucleic acid co-delivery technologies struggle to achieve precise quantitative control of the content of each nucleic acid and a controllable release sequence, resulting in low expression efficiency of nucleic acid drugs within cells and cumbersome and costly procedures.

Method used

By employing high-frequency oscillatory shearing microfluidic technology, different nucleic acid drugs are layered and encapsulated in specific regions of lipid nanoparticles by controlling the microfluidic shearing force and frequency, thereby achieving controllable time-sequential release and expression.

Benefits of technology

It enables precise encapsulation and release timing control of nucleic acid drugs, improving their efficacy and safety. It is applicable to various types of nucleic acid and lipid formulations, and the process is simple, rapid, and easy to scale up, making it suitable for on-site preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026101910_12112026_PF_FP_ABST
    Figure CN2026101910_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A nucleic acid co-encapsulation method based on high-frequency oscillatory shear microfluidic technology and the use thereof. By means of regulating the microfluidic shear force and frequency, different nucleic acid drug molecules are encapsulated in a layered manner in specific regions (periphery or core) of liposomal nanoparticles, thereby realizing controllable sequential release and expression. The method fundamentally solves the problem of precise encapsulation and sequential release control of different nucleic acids, so as to improve the efficacy and safety of nucleic acid drugs. The method is applicable to the preparation of related products in fields such as tumor vaccines, infectious disease prevention and gene therapy.
Need to check novelty before this filing date? Find Prior Art

Description

A method for co-encapsulating nucleic acids based on high-frequency oscillatory shearing microfluidic technology and its application Technical fields:

[0001] This invention belongs to the field of biomedical technology, specifically relating to a method and application of nucleic acid co-encapsulation based on high-frequency oscillation shearing microfluidic technology. Background technology:

[0002] In recent years, nucleic acid co-delivery therapies based on lipid nanoparticles (LNPs) have shown great potential in vaccine development, cancer treatment, and protein replacement therapy. However, existing nucleic acid co-delivery technologies still face many key bottlenecks.

[0003] First, traditional nucleic acid co-delivery methods struggle to precisely control the content of each nucleic acid during co-encapsulation. In traditional nucleic acid co-encapsulation (reference: Int J Pharm 626, 122171 (2022)), different nucleic acids are first mixed and dissolved together, and then self-assembled with liposomes to form a nucleic acid-LNP complex. Due to the randomness of the self-assembly process, the content and proportion of each nucleic acid encapsulated in each LNP are not uniform, and different nucleic acids often compete with each other for LNPs, making it difficult to achieve precise quantitative control of the content of different nucleic acids in the LNP.

[0004] Secondly, the randomness of the nucleic acid encapsulation process leads to an unordered release sequence of co-encapsulated nucleic acids. Random release of different nucleic acids may trigger competition for translational resources within the cell, reducing the expression efficiency of the target protein. Although some studies have attempted to mix several pre-encapsulated nucleic acid-LNPs containing only one type to form a co-delivery scheme similar to a "nucleic acid drug cocktail," this method cannot ensure that cells can uniformly take up each nucleic acid-LNP, nor can it ensure that each nucleic acid-LNP can be released and expressed on demand within the cell. Furthermore, traditional nucleic acid co-encapsulation methods rely on the participation of organic solvents, inevitably introducing subsequent purification procedures, resulting in cumbersome steps and high costs.

[0005] To address the aforementioned issues, existing technologies attempt to enhance the expression of target nucleic acids in cells by adjusting lipid formulations or optimizing nucleic acid sequences. However, these methods fail to fundamentally solve the challenge of precisely controlling the timing of encapsulation and release of different nucleic acids. Therefore, there is an urgent need for a technology capable of precisely controlling the encapsulation location, release sequence, and expression timing of nucleic acids to improve the efficacy and safety of nucleic acid drugs. Summary of the Invention:

[0006] To address the shortcomings of existing technologies, this invention proposes a nucleic acid co-encapsulation method and its application based on high-frequency oscillatory shearing microfluidic technology. By regulating the microfluidic shearing force and frequency, different nucleic acid drug molecules are layered and encapsulated in specific regions (peripheral or core) of lipid nanoparticles (LNPs), achieving controllable time-sequential release and expression. This fundamentally solves the problem of precise encapsulation and release timing control of different nucleic acids, thereby improving the efficacy and safety of nucleic acid drugs.

[0007] To address the problems in the existing technology, the present invention adopts the following technical solution:

[0008] A method for co-encapsulating nucleic acids (NAs) based on high-frequency oscillatory shearing microfluidics includes the following steps:

[0009] S1. Construct a microfluidic chip, wherein the microfluidic chip includes an internally arranged obstacle structure with staggered arrangement, wherein the height of the microfluidic channel is 10-1000μm and the width is 10-1000μm, the size of the obstacle is 10%-80% of the channel width, and the obstacles are arranged in a staggered manner with a spacing of 50-1000μm;

[0010] S2. Ionizable cationic lipids, auxiliary lipids, and polyethylene glycol-modified lipids are dissolved in an organic solvent to form a liposome solution; the first nucleic acid NA1 is dissolved in an acidic buffer to obtain NA1 buffer; the liposome solution and NA1 buffer are then rapidly mixed by stirring, shaking, or microfluidic technology to form NA1-encapsulated liposome nanoparticles, denoted as NA1-LNP; finally, residual organic solvent and unencapsulated NA1 in NA1-LNP are removed by tangential flow filtration or dialysis, and the solution is replaced with a neutral buffer to obtain the NA1-LNP solution to be used.

[0011] S3. Dissolve the second nucleic acid NA2 in an acidic buffer solution to obtain an NA2 solution;

[0012] S4. Inject the NA1-LNP solution and NA2 solution into the microfluidic chip described in S1 at a flow rate ratio of 1:0.1-10, adjust the pH to 3.0-6.0, and under preset temperature, fluid shear force and oscillation frequency conditions, use the high-frequency oscillating shear flow to insert NA2 into the lipid shell of NA1-LNP, while causing the previously encapsulated NA1 to migrate to the LNP core, forming a NA2-NA1-LNP complex with a layered structure; wherein, in the NA2-NA1-LNP complex, NA2 is located on the periphery of LNP and NA1 is located in the core of LNP.

[0013] Preferably, the obstacle in step S1 is triangular, semi-circular, or square in shape.

[0014] More preferably, the obstacles are staggered triangular obstacles. The obstacle spacing D is optimized to be 100-600μm and the microfluidic channel width to be 100-500μm through COMSOL Multiphysics fluid simulation to ensure that the required shear force F is 0.01-10.0pN and the shear flow reversal frequency f is 1-10000Hz.

[0015] Preferably, the neutral buffer in step S2 is a Tris solution, PBS solution, or DPBS solution with a pH of 6-8.

[0016] Preferably, the organic solvent in step S2 is ethanol.

[0017] Preferably, the accessory lipids in the first nucleic acid-LNP complex in step S2 include phospholipids or cholesterol.

[0018] Preferably, the ionizable cationic lipid in step S2 is selected from one of ALC-0315, SM-102, MC-3, and DOTAP.

[0019] Preferably, the acidic buffer solution in steps S2 and S3 is a sodium citrate buffer solution or sodium acetate buffer solution with a pH of 3-6.

[0020] Preferably, the first nucleic acid in step S2 and the second nucleic acid in step S3 are independently selected from any two of mRNA, self-amplified RNA (saRNA), circular RNA (circRNA), or plasmid DNA, with a length of 100-20,000 nt. It should be noted that when the first and second nucleic acids are of the same type, their sequences are different, which achieves different encapsulation and / or release effects.

[0021] Preferably, in step S4, the volume ratio of NA1-LNP solution to NA2 solution is 1:1; the preset temperature is 25-90℃, the pH is adjusted to 4.5, and the sum of the flow rates of NA1-LNP solution and NA2 solution is 0.05-5 mL / min.

[0022] Applications of the NA2-NA1-LNP complex with a layered structure prepared by any of the above methods in preventive vaccines, cancer treatment, and gene editing. Beneficial effects:

[0023] Compared with existing technologies, this invention provides a nucleic acid co-encapsulation method and application based on high-frequency oscillatory shearing microfluidic technology. This method uses high-frequency oscillatory shearing force to encapsulate different nucleic acid drugs stepwise and layeredly into different regions of a carrier, achieving a controllable release sequence and expression timing. Specific advantages are as follows:

[0024] (1) Precise spatiotemporal control: Through precise control of microfluidic shear force, different nucleic acids are hierarchically positioned (periphery / core) and released sequentially (outer first, then inner) within LNP, solving the problem of release order that cannot be controlled by traditional methods.

[0025] (2) Broad compatibility and universality: This method is applicable to a variety of nucleic acids (linear mRNA, circular RNA, self-amplified RNA, DNA, 1-13kb) and a variety of clinically commonly used lipid formulations (ALC-0315, SM-102, MC-3, DOTAP), and can be upgraded without changing the composition of the original LNP.

[0026] (3) The process is simple, fast, and easy to scale up: the entire process is completed within seconds, without the use of organic solvents or subsequent purification steps, and the product can be used directly. Through integrated desktop prototyping equipment, continuous production (200 doses / hour) can be achieved with small batch-to-batch differences (RSD<5%), which is very suitable for point-of-care preparation. Attached image description:

[0027] Figure 1 is a schematic diagram of the microfluidic chip structure of the present invention, (a) is a 2D planar top view of the microfluidic chip, and (b) is a 3D structural perspective view of the microfluidic chip.

[0028] Figure 2 is a schematic diagram of the high-frequency directional shear flow generated in the microfluidic chip of the present invention. (a) is a schematic diagram of the fluid changing its flow direction when passing through an obstacle. (b) is the shear rate in the microfluidic channel simulated by COMSOL commercial software.

[0029] Figure 3 is a schematic diagram of the mechanism of different nucleic acid layer encapsulation and time-sequential release achieved by the method of the present invention. (a) is a schematic diagram of the mechanism of different nucleic acid layer encapsulation, and (b) is a schematic diagram of the mechanism of different nucleic acid time-sequential release.

[0030] Figure 4 shows the encapsulation efficiency (a) and in vitro release curve (b) of ND and Spike mRNA of ND / Spike mRNA-LNP obtained in Example 1, wherein ND mRNA is released preferentially and Spike mRNA is released later.

[0031] Figure 5 shows the nucleic acid layering and encapsulation results of ND / Spike mRNA-LNP obtained in Example 1 under a confocal microscope, where ND mRNA is located in the outer layer of LNP (green fluorescence) and Spike mRNA is located in the inner layer of LNP (blue fluorescence). LNP is red fluorescence;

[0032] Figure 6 shows the expression levels of ND mRNA and Spike mRNA of ND / Spike mRNA-LNP obtained in Example 1 after transfection into cells;

[0033] Figure 7 shows the encapsulation efficiency (a) and in vitro release curve (b) of Spike and ND mRNA in Spike / ND mRNA-LNP obtained in Example 2, wherein Spike mRNA is released preferentially and ND mRNA is released later.

[0034] Figure 8 shows the nucleic acid layering and encapsulation results of Spike / ND mRNA-LNP obtained in Example 2 under a confocal microscope. ND mRNA is located in the inner layer of LNP (green fluorescence), and Spike mRNA is located in the outer layer of LNP (blue fluorescence). LNP is red fluorescence.

[0035] Figure 9 shows the expression levels of Spike mRNA and ND mRNA of Spike / ND mRNA-LNP obtained in Example 2 after transfection into cells;

[0036] Figure 10 shows that samples prepared by different methods exhibit decisive advantages in (a) encapsulation efficiency of the second nucleic acid, (b) particle size control, and (c) polydispersity index (PDI). Detailed implementation method:

[0037] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0038] When a fluid passes through an obstacle structure, it generates corresponding shear force and changes its flow direction. This invention defines the number of times the fluid changes direction in the microfluidic channel per second as the fluid oscillation frequency, thereby precisely controlling the fluid shear force and oscillation frequency generated by the microfluidic channel by changing the fluid velocity.

[0039] Example 1

[0040] Figure 1 is a schematic diagram of the microfluidic chip structure of the present invention. A microfluidic device is built according to this structure.

[0041] The interior is equipped with periodically arranged obstacle structures, in which the height of the microfluidic channel is 100μm and the width of the channel is 100μm. The obstacle shape is an equilateral triangle, and the size of the obstacle can be 50% of the width of the channel. The obstacles are arranged in a staggered manner with a spacing of 300μm.

[0042] As shown in Figure 2, in this embodiment, the obstacles are staggered triangular obstacles. The obstacle spacing D is optimized to 300 μm and the microfluidic channel width to 100 μm through COMSOL Multiphysics fluid simulation to ensure that the required shear force F is 0.1-5.0 pN and the shear flow reversal frequency f is 2000-8000 Hz.

[0043] Example 2

[0044] Using SARS-CoV-2 Spike mRNA (approximately 4,000 nt) as NA1 (referencing published literature Antiviral Research 212(2023):105556), the following experiments were conducted following the procedures described in the literature (Nat Commun 14,5925(2023)):

[0045] First, ionizable cationic lipids (ALC-0315), auxiliary lipids (DSPC and cholesterol), and polyethylene glycol-modified lipids (ALC-0159) were dissolved in an ethanol solution (total liposome mass concentration was 15.26 mg / mL).

[0046] Next, SARS-CoV-2 Spike mRNA was dissolved in sodium citrate acidic buffer solution with a pH of 4.0 and a mass concentration of 0.2 mg / mL; then the two were instantaneously mixed using a conventional microfluidic device to obtain the crude product.

[0047] Subsequently, ethanol solvent and unencapsulated impurities were removed by tangential flow filtration and the mixture was then transferred to 1X PBS buffer to obtain SARS-CoV-2 Spike mRNA-LNP at a concentration of 0.5 mg / mL.

[0048] NADH dehydrogenase ND mRNA (approximately 5,800 nt) was dissolved in sodium citrate buffer at pH 4.0 to achieve a concentration of 0.5 mg / mL (sequence reference NCBI Reference Sequence Database (RefSeq): subunit 1 YP_003024026.1, subunit 2 YP_003024027, subunit 3 YP_003024033.1, subunit 4 YP_003024035.1, subunit 5 YP_003024036.1, and subunit 6 YP_003024037.1). The ND mRNA solution and SARS-CoV-2 Spike mRNA-LNP solution were mixed at a 1:1 flow ratio and a total flow rate of 0.3 mL / min to adjust the pH to 4.5. The reaction temperature was controlled at 75 °C. The solution was encapsulated using the microfluidic device built in Example 1, wherein the shear force F was 2.5 pN and the shear flow reversal frequency f was 4000 Hz.

[0049] Encapsulation rates of ND mRNA and Spike mRNA were >90% (Figure 4(a)), with ND mRNA release prior to Spike mRNA (Figure 4(b)). High-resolution confocal microscopy characterization revealed a layered LNP with ND mRNA in the outer layer and Spike mRNA in the core (Figure 5). After transfection of 293T cells (commercially available product), both nucleic acids showed significant cellular expression levels (Figure 6).

[0050] Example 3

[0051] Using ND mRNA as NA1 and SARS-CoV-2 Spike mRNA (4,000 nt) as NA2, and following the preparation method in Example 2 and the microfluidic device constructed in Example 1, the encapsulation efficiency of ND mRNA and Spike mRNA was >90% (Figure 7(a)), and the release order of ND mRNA was preferential to that of Spike mRNA (Figure 7(b)). High-resolution confocal microscopy characterization showed that a layered LNP was obtained, with ND mRNA in the outer layer and Spike mRNA in the core (Figure 8). After transfection of 293T cells (commercially available product), both nucleic acids showed significant cellular expression levels (Figure 9).

[0052] Example 4

[0053] Under the condition that the channel cross-section (100μm×100μm) and flow rate (0.1mL / min) are consistent, fluid dynamics simulation confirms (Figure 10(a)) that the channel of the present invention can generate high-frequency oscillating shear flow due to its unique obstacle design. The shear force amplitude and action mode are far superior to the stable laminar flow generated by the traditional linear microfluidic channel (the channel cross-section is also 100μm×100μm, and the total length is equal to the channel length of the present invention). This optimized shear field is directly converted into the key quality indicators of the final product.

[0054] Using a commercially available Ribogreen fluorescence reagent kit, it was found that the ND / Spike mRNA-LNP complex prepared by the technology of this invention exhibited higher ND mRNA encapsulation efficiency compared with traditional linear microfluidic channels (Figure 10(b)), demonstrating its superior ability in nucleic acid co-encapsulation. Using a Malvern dynamic light scattering instrument, it was found that the ND / Spike mRNA-LNP complex prepared by the technology of this invention has a smaller average particle size and a lower polydispersity index (PDI), reflecting its superior performance in effectively inhibiting LNP aggregation and forming uniform nanoparticles.

[0055] In summary, this invention achieves hierarchical localization (peripheral / core) and sequential release (outer first, then inner) of different nucleic acids within a LNP through precise microfluidic shear force control. This solves the release sequence problem that traditional methods cannot control. It is applicable to various types of nucleic acids (linear mRNA, circular RNA, self-amplifying RNA, DNA, 1-13kb) and various clinically commonly used lipid formulations (ALC-0315, SM-102, MC-3, DOTAP), and can be upgraded without changing the composition of the original LNP. Comparative experiments have confirmed the technological advancement and effectiveness of this invention's method compared to traditional methods in achieving efficient and controllable nucleic acid co-encapsulation. The entire process is completed within seconds, requiring no organic solvents or subsequent purification steps; the product is ready for direct use. Through an integrated desktop prototype device, continuous production (200 doses / hour) can be achieved with minimal batch-to-batch variation (RSD < 5%), making it ideal for point-of-care preparation.

Claims

1. A method for co-encapsulation of nucleic acids based on high frequency oscillation shear microfluidic technology, characterized in that, The method comprises the following steps: S1. Building a microfluidic chip comprising staggered obstacle structures inside, wherein the height of the microfluidic channel is 10-1000 μm, the width is 10-1000 μm, the size of the obstacle is 10%-80% of the channel width, the obstacles are relatively staggered, and the spacing is 50-1000 μm; S2. Dissolving ionizable cationic lipids, auxiliary lipids and polyethylene glycol modified lipids in an organic solvent to form a liposome solution; dissolving a first nucleic acid NA1 in an acidic buffer to obtain an NA1 buffer; then mixing the liposome solution and the NA1 buffer by stirring, oscillation or microfluidic technology to quickly mix the liposome and the NA1 to form a liposome nanoparticle encapsulating the NA1, denoted as NA1-LNP; finally, removing the residual organic solvent and unencapsulated NA1 in the NA1-LNP by tangential flow filtration or dialysis method, and replacing it into a neutral buffer to obtain a ready-to-use NA1-LNP solution; S3. Dissolving a second nucleic acid NA2 in an acidic buffer to obtain an NA2 solution; S4. Co-injecting the NA1-LNP solution and the NA2 solution into the microfluidic chip of S1 at a flow rate ratio of 1:0.1-10, adjusting the pH to 3.0-6.0, and under the conditions of pre-set temperature, fluid shear force and oscillation frequency, using the high-frequency oscillatory shear flow to insert NA2 into the periphery of the lipid shell of NA1-LNP, while making the originally encapsulated NA1 migrate to the LNP core to form a NA2-NA1-LNP complex with a layered structure; wherein the NA2 in the NA2-NA1-LNP complex is located in the periphery of the LNP, and the NA1 is located in the core of the LNP.

2. The method according to claim 1, wherein, The shape of the obstacle in step S1 is a triangle, a semicircle or a square.

3. The method according to claim 2, wherein the high frequency oscillation shear microfluidic technique is characterized in that, The obstacle is a staggered triangular obstacle, and the obstacle spacing D is optimized to 100-600 μm and the microfluidic channel width is optimized to 100-500 μm by COMSOL Multiphysics fluid simulation to ensure that the required shear force F is 0.01-10.0 pN and the shear flow direction frequency f is 1-10000 Hz.

4. The method according to claim 1, wherein, The neutral buffer in step S2 is a tris solution, a PBS solution or a DPBS solution with pH 6-8; the organic solvent is ethanol.

5. The method according to claim 1, wherein, The auxiliary lipids in the first nucleic acid-LNP complex in step S2 include phospholipids or cholesterol.

6. The method according to claim 1, wherein, The ionizable cationic lipids in step S2 are selected from one of ALC-0315, SM-102, MC-3 and DOTAP.

7. The method according to claim 1, wherein, The acidic buffer in steps S2 and S3 is a sodium citrate buffer solution or a sodium acetate buffer solution with pH 3-6.

8. The method according to claim 1, wherein, The first nucleic acid in step S2 and the second nucleic acid in step S3 are independently selected from any two of mRNA, self-amplifying RNA (saRNA), circular RNA (circRNA) or plasmid DNA, and have a length of 100-20,000 nt. It should be noted that when the types of the first nucleic acid and the second nucleic acid are the same, the sequences of the two are different, which realizes different encapsulation and / or release.

9. The method according to claim 1, wherein, In step S4, the volume ratio of the NA1-LNP solution and the NA2 solution is 1:1; the preset temperature is 25-90°C, the pH is adjusted to 4.5, and the sum of the flow rates of the NA1-LNP solution and the NA2 solution is 0.05-5 mL / min.

10. Application of the NA2-NA1-LNP complex with a layered structure prepared based on the method of any one of claims 1-9 in prophylactic vaccines, cancer treatment, gene editing.